Investigation of crucial genes and microRNAs in conventional osteosarcoma using gene expression profiling analysis
- Authors:
- Published online on: September 18, 2017 https://doi.org/10.3892/mmr.2017.7506
- Pages: 7617-7624
Abstract
Introduction
Osteosarcoma (OS) is the most common malignancy of bone in early adolescence (1). Conventional OS, also termed classical OS, is a common type of OS and is universally life-threatening due to its rapid growth, high local aggression and metastatic potential (2). During previous years, considerable progress has been made in identifying the key components in conventional OS, including genes, pathways and microRNAs (miRNAs). For example, during osteoblast differentiation, miRNA (miR)-34 is significantly induced by bone morphogenetic protein 2, and regulates multiple components of the Notch signalling pathway, including Notch1, Notch2 and jagged 1, which affects osteoclast differentiation. This regulatory association may be closely associated with the pathogenesis of OS (3). In addition, phosphatase and tensin homolog (PTEN) has been found to be a potent regulator of the phosphatidylinositol 3-kinase (PI3K) /serine-threonine kinase (Akt) pathway (4), and the loss of PTEN is a common occurrence in conventional OS (5). A previous study has showed that the expression of PTEN can be inhibited by miR-221, which potentiates the PI3K/Akt pathway in the conventional pathogenesis of OS (6). PTEN is also a target of miR-92a, and of members of the miR-17 and miR-130/301 families in OS (7).
In 2010, using genome-wide microarrays, Fritsche-Guenther et al (8) found that the aberrant expression of ephrin receptor A2 (EphA2) and its ligand, EFNA1 in OS can modulate the activation of the mitogen-activated protein kinase (MAPK) pathway. In addition, it was found that the expression of CD52 was higher in OS metastases compared with conventional OS metastases, and CAMPATH-1H, an antibody directed against CD52, reduced the number of viable OS cells (9). In 2013, Luo et al (10) found numerous differentially expressed genes (DEGs) and regulatory associations between transcription factors and DEGs in OS using the microarray data deposited by Fritsche-Guenther et al For example, interleukin 6 can be regulated by tumour protein p53 (TP53), nuclear factor I/C (CCAAT-binding transcription factor), retinoic acid receptor α, and CCAAT/enhancer binding protein β. In 2014, Yang et al (11) also identified a number of DEGs, Gene Ontology (GO) terms, including protein binding, and significant pathways, including focal adhesion, in OS based on a meta-analysis of eight expression profiles, including the one deposited by Fritsche-Guenther (8). However, in these previous studies, the potential miRNAs and regulatory associations between miRNAs and DEGs in OS were not examined.
In the present study, to screen and identify additional DEGs and miRNAs in conventional OS, the microarray data deposited by Fritsche-Guenther (8) were downloaded. Following GO and pathway enrichment analyses, and construction of a protein-protein interaction (PPI) network for the DEGs, the potential miRNAs in the most significant pathway for the upregulated DEGs were identified, and a regulatory network for the miRNAs-DEGs was constructed. The results were expected to assist in elucidating the aetiology of conventional OS, and provide more information to assist in the clinical diagnosis and treatment of this disease.
Materials and methods
Affymetrix microarray data
The GSE14359 (8) gene expression profile data were acquired from the Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/), which was based on the platform of the GPL96 [HG-U133A] Affymetrix Human Genome U133A Array. This dataset contains 10 conventional OS samples from the femur or tibia (two replicates each) from five consenting patients with grade 2–3 conventional OS between 7 and 74 years of age; eight OS lung metastasis tumour samples (two replicates each) from four consenting patients with a grade 1–3 OS lung metastatic tumour; and two non-neoplastic primary osteoblast cell samples with limited life span in vitro from one patient (two replicates). These 10 conventional OS samples and two non-neoplastic primary osteoblast samples were selected for further analysis.
The CEL files and probe annotation files were downloaded, and the gene expression data of all samples were preprocessed via background correction, quantile normalization and probe summarization using the Gene Chip Robust Multi Array algorithm (12) in the Affy software package (version 1.32.0; http://www.bioconductor.org/packages/release/bioc/html/affy.html) (13).
DEG screening
The Linear Models for Microarray Data package (version 3.10.3; http://www.bioconductor.org/packages/2.9/bioc/html/limma.html) (14) of R was used to identify genes, which were significantly differentially expressed in the conventional OS samples. The raw P-value was adjusted by the Benjamin and Hochberg method (15), and only genes meeting the cut-off criteria of |log2 fold-change|>1 and adjusted P<0.01 were selected as DEGs.
Hierarchical clustering analysis of the DEGs
Hierarchical clustering is a common method used to determine clusters of similar data points in multidimensional spaces (16). The pheatmap package (version 1.08; https://cran.r-project.org/web/packages/pheatmap/) (17) was used to perform hierarchical clustering via joint between-within distances for the DEGs in the conventional OS and non-neoplastic primary osteoblasts samples.
GO and pathway enrichment analyses
The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a set of comprehensive functional annotation tools, which can be used to identify the biological meanings of abundant genes (18). P<0.01 was used as the cut-off criterion for GO and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis using DAVID (version 6.7; https://david-d.ncifcrf.gov/), based on the hypergeometric distribution algorithm.
PPI network construction
The Search Tool for the Retrieval of Interacting Genes database (version 10.0; http://string-db.org/), which provides experimental and predicted interaction information (19), was used to analyse the PPIs for DEGs by calculating the combined score, and a score >0.4 was selected as the cut-off criterion. Subsequently, the PPI network of the upregulated and downregulated DEGs was visualized using Cytoscape (version 3.2.0; http://cytoscape.org/) (20).
Screening and analysis of network modules
The network modules were obtained based on Molecular Complex Detection (MCODE) analysis (21) of the original PPI networks. The default parameters (degree cut-off, 2; node score cut-off, 0.2; K-core, 2) were used as the cut-off criteria for the network module screening.
In order to obtain further information on the gene functions and identify pathways closely associated with the DEGs, functional annotation analysis and subsequent pathway enrichment analysis of the network module with the highest MCODE score were performed using DAVID, with a P<0.01 cut-off.
Integrated miRNA-DEG regulatory network construction
The potential miRNAs for upregulated DEGs in the most significant pathway were predicted using the miRDB database (version 1.24.0; http://www.bioconductor.org/packages/2.8/bioc/html/maDB.html) (22), with a cut-off for the target score of ≥60. The binding sites of miRNAs in the human mRNAs > 800 were abandoned. The integrated miRNA-DEG regulatory network was then visualised with Cytoscape.
Results
Identification of DEGs
Following the data preprocessing, 11,107 probes were obtained. Based on the cut-off criteria, a total of 987 DEGs were screened from the conventional OS samples, including 317 upregulated genes and 670 downregulated genes. The hierarchical cluster analysis of the data revealed that it was possible to use the DEGs to accurately distinguish the conventional OS samples from the non-neoplastic primary osteoblast cell samples (Fig. 1).
Enrichment analysis of upregulated and downregulated DEGs
According to the GO functional annotation, the upregulated DEGs were predominantly enriched in GO terms associated with DNA replication, including MCM3, replication factor C (RFC)5, replication protein A3 (RPA3) and flap endonuclease 1 (FEN1), and cell cycle, including cyclin-dependent kinase 1 (CDK1), NDC80 kinetochore complex (NDC80), BUB1 mitotic checkpoint serine/threonine-protein kinase (BUB1) and mitotic arrest deficient 2 like 1 (MAD2L1). A number of downregulated DEGs, including caveolin 1 (CAV1), cadherin 13 (CDH13), vascular endothelial growth factor C (VEGFC) and transforming growth factor β receptor 3 (TGFBR3), were relevant to blood vessel development, whereas epidermal growth factor receptor (EGFR), TP53, VEGFB and MAPK1 were associated with the regulation of cell proliferation (Table IA).
According to the results of the pathway enrichment analysis, the upregulated DEGs were predominantly enriched in seven pathways. In accordance with the GO term analysis, the DNA replication pathway, including RFC2, RFC3, RFC4 and RFC5, and cell cycle pathway, including CDK1, minichromosome maintenance complex component 3 (MCM3) and BUB1, were also enriched in the upregulated genes. The downregulated DEGs were predominantly enriched in the focal adhesion, including CAV1, collagen type VI α1 (COL6A1), thrombospondin 1 (THBS1) and EGFR, and p53 signalling pathways, including TP53, Fas cell surface death receptor (FAS) and TP53 apoptosis effector (PERP), as shown in Table IB.
Construction and analysis of the PPI network
The PPI network for the upregulated and downregulated DEGs consisted of 442 pairs of PPIs. The degrees of DEGs, including CDK1, MAD2L1, NDC80, non-SMC condensin I complex subunit G (NCAPG), BUB1, centromere protein F (CENPF) and kinesin family member 11 (KIF11), were >17 (Table II), indicating that they were important genes in OS.
Table II.Differentially expressed genes with a connectivity degree of ≥10 in the protein-protein interaction network. |
Analysis of network modules
A total of 10 network modules were obtained from the PPI network using the default criteria, and the module with the highest score contained 16 nodes and 102 edges. In this module, CDK1 interacted with other DEGs, including MAD2L1, BUB1, NCAPG, NDC80 and CENPF (Fig. 2).
The functional enrichment analysis of the module with the highest score showed that the majority of the DEGs in this module were predominantly associated with the cell cycle. Certain DEGs, including CDK1, MAD2L1, BUB1 and NDC80, were implicated in mitosis and the M phase of mitotic cell cycle; other DEGs, including Rac GTPase-activating protein 1 (RACGAP1) and MAD2L1, were correlated with cell cycle process (Table IIIA). CDK1, MAD2L1, BUB1 and aurora kinase A (AURKA) were significantly enriched in the oocyte meiosis pathway (Table IIIB).
Analysis of the miRNA-DEG regulatory network
The miRNA-DEG regulatory network contained 63 miRNAs, nine of their corresponding DEGs and 16 DEGs, which interacted with these nine DEGs. DNA polymerase ζ subunit 3 (POLE3) was regulated by 18 miRNAs, including miR-4310, miR-4680-3p, miR-583 and miR-4269; RFC3 was regulated by 16 miRNAs, including miR-802 and miR-649; RFC3 and RFC5 were modulated by miR-522-3p and miR-224-3p. In addition, RFC2, RFC3, RFC4 and RFC5 interacted with each other (Fig. 3).
Discussion
In the present study, 317 DEGs were found to be significantly upregulated and 670 were significantly downregulated in the conventional OS samples. A majority of the DEGs were associated with cell cycle. According to the miRNA-DEG regulatory network for the DEGs enriched in DNA replication, RFC2, RFC3, RFC4 and RFC5 were found to interact with each other.
RFC2, RFC3, RFC4 and RFC5 encode members of RFC family, also termed activator 1. These DEGs were enriched in DNA replication, which agreed with the results of previous studies (23,24). DNA replication is an essential event in tumour growth (25). The deregulation of protein complexes involved in the initiation of DNA replication can lead to cancer (26). Several DEGs in the network module, including CDK1, MAD2L1, NDC80 and BUB1, which had higher degrees in the PPI network, were found to interact with RFC4. These four DEGs were predominantly enriched in cell mitosis and cell cycle. Alterations in cell cycle regulation occur in several types of cancer, including OS (27). Cyclin-dependent kinase 1 (CDK1) is an important G2/M checkpoint protein (28), and its inhibitor, SCH 727965 (dinacliclib) can trigger the apoptosis of U-2 OS cells (29). MAD2L1, BUB1 and NDC80 are involved in the spindle checkpoint pathway (30,31). MAD2 has been reported to be commonly overexpressed in human conventional OS (32), and BUB1 has been found to be ectopically expressed in SAOS and U-2 OS cell lines (33). In addition, CDK1, MAD2L1 and BUB1 have been found to be significantly enriched in the pathway of oocyte meiosis, which was found to be markedly altered in high-grade OS cell lines when compared with osteoblasts (34). RFC3 was also modulated by a cluster of miRNAs, including miR-802. The expression of miR-802 has been reported to be upregulated in OS tissues, and to promote cell proliferation by targeting p27 in U-2 OS and MG-63 cells (35). RFC3 and RFC5 are also modulated by miR-224-3p and miR-522-3p. There is no previous evidence indicating that miR-224-3p and miR-522-3p are associated with conventional OS. Therefore, miR-224-3p and miR-522-3p are predicted to be novel biomarkers in conventional OS. Therefore, RFC2-5, together with certain DEGs, including CDK1, MAD2L1, NDC80 and BUB1, and a series of miRNAs, including miR-802, miR-224-3p and miR-522-3p, may be responsible for the initiation and development of conventional OS.
In conclusion, the present study found that the majority of DEGs, including CDK1, MAD2L1, NDC80 and BUB1, were associated with the cell cycle. Other DEGs, including RFC2, RFC3, RFC4 and RFC5, were associated with DNA replication. These, in addition to a number of miRNAs, including miR-802, miR-224-3p and miR-522-3p, may be essential in the pathogenesis of conventional OS, providing novel information to assist in the clinical diagnosis of this disease. However due to limitations in the present study, additional experiments are required to shed light on the molecular mechanisms involved in this life-threatening disease.
References
Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM and Getty PJ: Osteosarcoma. J Am Acad Orthop Surg. 17:515–527. 2009. View Article : Google Scholar : PubMed/NCBI | |
Mohseny AB, Tieken C, Van Der Velden PA, Szuhai K, de Andrea C, Hogendoorn PC and Cleton-Jansen AM: Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma. Genes Chromosomes Cancer. 49:1095–1103. 2010. View Article : Google Scholar : PubMed/NCBI | |
Bae Y, Yang T, Zeng HC, Campeau PM, Chen Y, Bertin T, Dawson BC, Munivez E, Tao J and Lee BH: miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet. 21:2991–3000. 2012. View Article : Google Scholar : PubMed/NCBI | |
Silva A, Yunes JA, Cardoso BA, Martins LR, Jotta PY, Abecasis M, Nowill AE, Leslie NR, Cardoso AA and Barata JT: PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest. 118:3762–3774. 2008. View Article : Google Scholar : PubMed/NCBI | |
Freeman SS, Allen SW, Ganti R, Wu J, Ma J, Su X, Neale G, Dome JS, Daw NC and Khoury JD: Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer. 113:1453–1461. 2008. View Article : Google Scholar : PubMed/NCBI | |
Zhao G, Cai C, Yang T, Qiu X, Liao B, Li W, Ji Z, Zhao J, Zhao H, Guo M, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PLoS One. 8:e539062013. View Article : Google Scholar : PubMed/NCBI | |
Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS One. 7:e480862012. View Article : Google Scholar : PubMed/NCBI | |
Fritsche-Guenther R, Noske A, Ungethüm U, Kuban RJ, Schlag PM, Tunn PU, Karle J, Krenn V, Dietel M and Sers C: De novo expression of EphA2 in osteosarcoma modulates activation of the mitogenic signalling pathway. Histopathology. 57:836–850. 2010. View Article : Google Scholar : PubMed/NCBI | |
Fritsche-Guenther R, Gruetzkau A, Noske A, Melcher I, Schaser KD, Schlag PM, Kasper HU, Krenn V and Sers C: Therapeutic potential of CAMPATH-1H in skeletal tumours. Histopathology. 57:851–861. 2010. View Article : Google Scholar : PubMed/NCBI | |
Luo Y, Deng Z and Chen J: Pivotal regulatory network and genes in osteosarcoma. Arch Med Sci. 9:569–575. 2013. View Article : Google Scholar : PubMed/NCBI | |
Yang Z, Chen Y, Fu Y, Yang Y, Zhang Y, Chen Y and Li D: Meta-analysis of differentially expressed genes in osteosarcoma based on gene expression data. BMC Med Genet. 15:802014. View Article : Google Scholar : PubMed/NCBI | |
Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F and Spencer F: A model-based background adjustment for oligonucleotide expression arrays. Journal of the American Statistical Association. 99:909–917. 2004. View Article : Google Scholar | |
Seo J and Hoffman EP: Probe set algorithms: Is there a rational best bet? BMC bioinformatics. 7:3952006. View Article : Google Scholar : PubMed/NCBI | |
Smyth GK: Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 3:Article32004. View Article : Google Scholar : PubMed/NCBI | |
Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological). 57:289–300. 1995. | |
Olson CF: Parallel algorithms for hierarchical clustering. Parallel Computing. 21:1313–1325. 1995. View Article : Google Scholar | |
Kolde R: pheatmap: Pretty Heatmaps. R package. version 0.7. 7. 2012. | |
Huang DW, Sherman BT, Tan Q, Collins JR, Alvord WG, Roayaei J, Stephens R, Baseler MW, Lane HC and Lempicki RA: The DAVID gene functional classification tool: A novel biological module-centric algorithm to functionally analyze large gene lists. Genome Biol. 8:R1832007. View Article : Google Scholar : PubMed/NCBI | |
Von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P and Snel B: STRING: A database of predicted functional associations between proteins. Nucleic Acids Res. 31:258–261. 2003. View Article : Google Scholar : PubMed/NCBI | |
Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI | |
Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI | |
Wang X: miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA. 14:1012–1017. 2008. View Article : Google Scholar : PubMed/NCBI | |
Reynolds N, Fantes PA and MacNeill SA: A key role for replication factor C in DNA replication checkpoint function in fission yeast. Nucleic Acids Res. 27:462–469. 1999. View Article : Google Scholar : PubMed/NCBI | |
Redondo-Muñoz J, Rodríguez MJ, Silió V, Pérez-García V, Valpuesta JM and Carrera AC: Phosphoinositide 3-kinase beta controls replication factor C assembly and function. Nucleic Acids Res. 41:855–868. 2013. View Article : Google Scholar : PubMed/NCBI | |
Loeb LA, Springgate CF and Battula N: Errors in DNA replication as a basis of malignant changes. Cancer Res. 34:2311–2321. 1974.PubMed/NCBI | |
Tsaniras S Champeris, Kanellakis N, Symeonidou IE, Nikolopoulou P, Lygerou Z and Taraviras S: Licensing of DNA replication, cancer, pluripotency and differentiation: An interlinked world? Semin Cell Dev Biol. 30:174–180. 2014. View Article : Google Scholar : PubMed/NCBI | |
PosthumaDeBoer J, van Royen B and Helder M: Mechanisms of therapy resistance in osteosarcoma: A review. Oncol Discov. 1:82013. View Article : Google Scholar | |
Kim MJ, Lee JY and Lee SJ: Transient suppression of nuclear Cdc2 activity in response to ionizing radiation. Oncol Rep. 19:1323–1329. 2008.PubMed/NCBI | |
Fu W, Ma L, Chu B, Wang X, Bui MM, Gemmer J, Altiok S and Pledger WJ: The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells. Mol Cancer Ther. 10:1018–1027. 2011. View Article : Google Scholar : PubMed/NCBI | |
Doak SH, Jenkins GJ, Parry EM, Griffiths AP, Baxter JN and Parry JM: Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression. Mutat Res. 547:133–144. 2004. View Article : Google Scholar : PubMed/NCBI | |
Giantin M, Granato A, Baratto C, Marconato L, Vascellari M, Morello EM, Vercelli A, Mutinelli F and Dacasto M: Global gene expression analysis of canine cutaneous mast cell tumor: Could molecular profiling be useful for subtype classification and prognostication? PLoS One. 9:e954812014. View Article : Google Scholar : PubMed/NCBI | |
Yu L, Guo WC, Zhao SH, Tang J and Chen JL: Mitotic arrest defective protein 2 expression abnormality and its clinicopathologic significance in human osteosarcoma. Apmis. 118:222–229. 2010. View Article : Google Scholar : PubMed/NCBI | |
Trougakos IP, Chondrogianni N, Amarantos I, Blake J, Schwager C, Wirkner U, Ansorge W and Gonos ES: Genome-wide transcriptome profile of the human osteosarcoma Sa OS and U-2 OS cell lines. Cancer Genet Cytogenet. 196:109–118. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC and Cleton-Jansen AM: IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer. 13:2452013. View Article : Google Scholar : PubMed/NCBI | |
Cao ZQ, Shen Z and Huang WY: MicroRNA-802 promotes osteosarcoma cell proliferation by targeting p27. Asian Pac J Cancer Prev. 14:7081–7084. 2013. View Article : Google Scholar : PubMed/NCBI |